High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy

IntroductionImmunotherapy has revolutionized cancer treatment, and Chimeric Antigen Receptor T cell therapy (CAR-T) is a groundbreaking approach. Traditional second-generation CAR-T therapies have achieved remarkable success in hematological malignancies, but there is still room for improvement, par...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jorge Gallego-Valle, Verónica Astrid Pérez-Fernández, Jesús Rosales-Magallares, Sergio Gil-Manso, María Castellá, Europa Azucena Gonzalez-Navarro, Rafael Correa-Rocha, Manel Juan, Marjorie Pion
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-09-01
Edice:	Frontiers in Immunology
Témata:	engineered cells immunosuppression Treg Chimeric Antigen Receptor streptavidin-based CAR
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1448752/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!